|
Erlotinib
API |
|
|
|
Haorui supplies high quality Erlotinib API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Erlotinib API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
|
|
|
What is Erlotinib HCl? |
| Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP,
originally coded as OSI-774) is a drug used to treat
non-small cell lung cancer, pancreatic cancer and several
other types of cancer. Erlotinib is a cancer chemotherapy
medication. Erlotinib interferes with the growth of cancer
cells and slows their growth and spread in the body.
Erlotinib is used in the treatment of non-small cell lung
cancer.
Erlotinib may also be used for purposes other than those
listed in this medication guide |
|
|
|
Overview of
Erlotinib HCl |
Similar to gefitinib, erlotinib specifically targets the
epidermal growth factor receptor (EGFR) tyrosine kinase,
which is highly expressed and occasionally mutated in
various forms of cancer. It binds in a reversible fashion to
the adenosine triphosphate (ATP) binding site of the
receptor.[1] For the signal to be transmitted, two members
of the EGFR family need to come together to form a homodimer.
These then use the molecule of ATP to autophosphorylate each
other, which causes a conformational change in their
intracellular structure, exposing a further binding site for
binding proteins that cause a signal cascade to the nucleus.
By inhibiting the ATP, autophosphorylation is not possible
and the signal is stopped.
Erlotinib has shown a survival benefit in the treatment of
lung cancer in phase III trials. It has been approved for
the treatment of locally advanced or metastatic non-small
cell lung cancer that has failed at least one prior
chemotherapy regimen. In November 2005, the FDA approved the
use of erlotinib in combination with gemcitabine for
treatment of locally advanced, unresectable, or metastatic
pancreatic cancer. The drug's patent will expire in 2020.
A test for the EGFR mutation in cancer patients has been
developed by Genzyme. This may predict who will respond to
erlotinib and other tyrosine kinase inhibitors. It is
reported that responses among patients with lung cancer are
seen most often in females who were never smokers,
particularly Asian women and those with adenocarcinoma cell
type.
Erlotinib has recently been shown to be a potent inhibitor
of JAK2V617F activity. JAK2V617F is a mutant of tyrosine
kinase JAK2, is found in most patients with polycythemia
vera (PV) and a substantial proportion of patients with
idiopathic myelofibrosis or essential thrombocythemia. The
study suggests that erlotinib may be used for treatment of
JAK2V617F-positive PV and other myeloproliferative
disorders. |
| |
|
How to use Erlotinib |
Use Erlotinib as directed by your doctor. Check the label on
the medicine for exact dosing instructions. Check the label
on the medicine for exact dosing instructions.
 | Erlotinib should be taken at
least 1 hour before or 2 hours after eating. |
| Wash your hands immediately
after taking Erlotinib . |
| Take Erlotinib regularly to
receive the most benefit from it. Taking Erlotinib at the
same time each day will help you to remember to take it.
|
| If you miss a dose of
Erlotinib , contact your doctor immediately. |
Ask your health care provider any questions you may have
about how to use Erlotinib. |
| |
|
Possible side effects of Erlotinib
|
|
Erlotinib may cause side effects. Tell
your doctor if any of these symptoms are severe or do not go
away:
| diarrhea
|
| nausea
|
| vomiting
|
| stomach pain
|
| loss of appetite
|
| mouth sores
|
| itching
|
| dry skin
|
| tiredness
|
Some side effects can be serious. If you
experience any of the following symptoms, call your doctor
immediately:
| rash
|
| new or worsening shortness of breath, cough, or fever
|
| sore throat, chills and other signs of infection
|
| unusual bruising or bleeding
|
| black and tarry stools
|
| red blood in stools
|
| bloody vomit
|
| vomiting material that looks like coffee grounds
|
| dry, red, or irritated eyes
|
| sunken eyes
|
| dry mouth
|
| decreased urination
|
| lack of energy
|
Erlotinib may cause other side effects.
Call your doctor if you have any unusual problems while
taking this drug. |
| |
|
Storage conditions |
| Keep erlotinib in the container it came in, tightly closed,
and out of reach of children. Store it at room temperature
and away from excess heat and moisture (not in the
bathroom). Throw away any medication that is outdated or no
longer needed. Talk to your pharmacist about the proper
disposal of your medication. |
| |
| |
| |
|
Disclaimer:
|
|
Information on this page is provided for
general information purposes. You should not make a clinical
treatment decision based on information contained in this
page without consulting other references including the
package insert of the drug, textbooks and where relevant,
expert opinion. We cannot be held responsible for any errors
you make in administering drugs mentioned on this page, nor
for use of any erroneous information contained on this
page. |
|
|
